Search

The article discusses a clinical trial, NCT06791187, investigating the impact of a single dose of BI 1291583 on the pharmacokinetics of dabigatran in healthy adult male subjects. The trial aims to explore the effect of BI 1291583, a P-glycoprotein substrate, on dabigatran, an anticoagulant. The study involves 14 male participants and focuses on parameters such as the area under the concentration-time curve of dabigatran in plasma. The trial is set to be completed by March 17, 2025, and is being conducted in Germany. [Extracted from the article]

Researchers from the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University in China have explored the recent development of micro-nano carriers for oral antineoplastic drug delivery in cancer gene therapy. They highlight the challenges of limited solubility and permeability of anti-tumor medications in gastrointestinal environments and discuss the potential of micro-nano drug carriers to improve drug efficacy. The study aims to inform the development of novel oral delivery carriers for future clinical applications in cancer treatment. [Extracted from the article]

A recent study conducted at the University of Pittsburgh focused on the effects of ethinyl estradiol therapy on menopausal symptoms in female common marmosets. The research found that both ethinyl estradiol and a brain-selective estrogen prodrug called DHED improved cognition and sleep in the marmoset menopause model. The study suggests that DHED could be a promising therapeutic option for alleviating cognitive and sleep disruptions associated with estrogen deficiency in primates. The research was supported by the National Institutes of Health (NIH) in the United States and has been peer-reviewed. [Extracted from the article]

A patent has been issued for a water-dissolvable nicotine tablet by Fertin Pharma A/S, designed to provide an improved user experience by addressing the burning sensation often associated with oral tobacco compositions. The tablet consists of a fast disintegrating tablet-module and a lozenge-module, with specific compositions and pH regulating agents to optimize nicotine delivery. The invention aims to enhance user expectations and experiences with nicotine consumption. [Extracted from the article]

Mitsubishi Tanabe Pharma Corporation has been issued a patent for a pharmaceutical composition containing edaravone for oral administration or intragastric administration. The invention aims to treat oxidative stress diseases, such as amyotrophic lateral sclerosis (ALS), by administering edaravone with specific time intervals after meals. The patent outlines methods for administering the pharmaceutical composition and includes detailed claims for treating ALS using edaravone. The patent provides valuable information for researchers and practitioners in the field of pharmaceuticals and health. [Extracted from the article]

A patent has been issued for treatments involving nirogacestat, a gamma-secretase inhibitor, by Springworks Therapeutics Inc. The patent focuses on using nirogacestat to treat conditions such as desmoid tumors, multiple myeloma, and ovarian granulosa cell tumors. The patent outlines specific dosages and administration methods for treating these conditions with nirogacestat, emphasizing the need for effective gamma-secretase inhibition in patients with these diseases. [Extracted from the article]

A study conducted at Cedars Sinai Medical Center in Los Angeles, California, explored the use of a synthetic RNA drug called TY1 in reversing heart failure with preserved ejection fraction (HFpEF) in mice. The research found that intravenous administration of TY1 effectively reversed cardiac and systemic manifestations of HFpEF without inducing weight loss. Additionally, oral administration of TY1 in a micellar formulation reproduced the effects seen with intravenous administration. This study suggests that TY1 may be a promising treatment for HFpEF due to its disease-modifying bioactivity. [Extracted from the article]

Researchers at the University of Rome Tor Vergata conducted a study on the effects of solid-lipid nanoparticles (SLNs) on pregnancy outcomes in female mice. The study involved oral administration of SLNs loaded with melatonin or unloaded at different dosages prior to mating. Results showed that SLN administration did not significantly impact pregnancy parameters, maternal health, or fetal development, indicating that SLNs as a drug delivery vehicle before conception pose no risk to future pregnancies. The research was published in Frontiers in Toxicology and conducted by a team of researchers from various institutions in Italy. [Extracted from the article]

Researchers from Shenyang Pharmaceutical University in Liaoning, China, have developed enteric-coated microcapsules to protect roxithromycin (ROX) from acid hydrolysis, enhancing its efficacy and solubility for oral administration, particularly beneficial for children and patients with swallowing difficulties. The microcapsules were created using polyvinylpyrrolidone (PVP) K30 and Eudragit L30 D-55 in a fluidized bed processor, inhibiting ROX crystallization and improving its dispersion and wettability. The study concluded that these microcapsules can effectively protect ROX stability in simulated gastric fluid and release over 75% of the drug in simulated intestinal fluid, showing promise for pharmaceutical applications. [Extracted from the article]

A study conducted by researchers at Shanghai Jiao Tong University focused on the pharmacokinetics and tissue distribution of major active components in Weikangling Capsules in normal and chronic gastritis rats. The study utilized advanced analytical methods to identify and compare the pharmacokinetic characteristics of these components. The findings provide a foundation for understanding the therapeutic effects of Weikangling Capsules in treating gastrointestinal disorders. The research was supported by the National Key Research & Development Program of China and was published in the Journal of Ethnopharmacology. [Extracted from the article]

Researchers at Radboud University Medical Center conducted a study comparing the antimycobacterial effect of inhaled versus oral administration of clofazimine in combination with an azithromycin-ethambutol backbone for treating Mycobacterium avium complex infections. The study found that inhaled clofazimine administration increased the antibiotic concentration at the site of infection, reducing systemic exposure and drug-induced toxicity. This research suggests that inhaled clofazimine with the azithromycin-ethambutol backbone may be more effective in treating these infections and reducing the development of macrolide resistance compared to oral administration. [Extracted from the article]

A patent has been issued for the treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor by Biora Therapeutics Inc. The patent focuses on topically administering a pharmaceutical formulation containing a JAK inhibitor to treat gastrointestinal inflammatory diseases or conditions. The method involves orally administering an ingestible device to release the formulation to specific locations within the GI tract, providing advantages over systemic administration. This patent highlights advancements in drug delivery methods for treating inflammatory bowel diseases and conditions. [Extracted from the article]

The patent application by Entera Bio Ltd. focuses on formulations for oral administration of therapeutically active agents, particularly peptide and protein pharmaceuticals. The application describes multi-unit dosage forms that disintegrate in gastric fluid or saliva, releasing the active agents and absorption enhancers. The goal is to improve the effectiveness and consistency of oral drug delivery, specifically targeting conditions treatable by parathyroid hormone or its fragments. The patent application emphasizes the use of specific absorption enhancers to enhance drug absorption and efficacy. [Extracted from the article]

A recent study conducted at University Hospital Poitiers in France focused on developing a new softgel for safe oral administration in pediatric patients. The researchers aimed to address the challenges of formulating pediatric medications due to poor solubility and permeability of active ingredients. The study validated a stability-indicating HPLC-UV analytical assay method for vitamin K, the first active ingredient tested in the softgel, which demonstrated better accuracy in delivering a safe dose compared to other forms. The research highlighted the need for further exploration of different active ingredients and formulations, as well as the practicality of implementing this technology in hospital pharmacies. [Extracted from the article]

A patent was issued to Epizyme Inc. for a method of treating cancer, specifically solid tumors, B cell lymphoma, or cancers with aberrant H3-K27 methylation. The method involves orally administering a compound called EPZ-6438 in specific dosages to achieve therapeutic effects. This patent addresses the ongoing need for new agents, such as EZH2 inhibitors, for anticancer treatment, focusing on personalized medicine approaches. The method outlined in the patent aims to provide effective treatment for various types of cancer, including lymphomas and solid tumors, by targeting specific genetic markers associated with cancer development. [Extracted from the article]

Researchers from Hubei University of Medicine in China conducted a study on the pharmacokinetics, bioavailability, and tissue distribution of MRTX1133 in rats using UHPLC-MS/MS. The study found that MRTX1133 was quickly absorbed, widely distributed in major organs, and had a bioavailability of 2.92%. The research provides valuable information for the quantitative determination of MRTX1133 in preclinical or clinical trials. For more details, the full article can be accessed for free at the Frontiers in Pharmacology website. [Extracted from the article]

Researchers have submitted a patent application for a method to reduce the aversiveness of bitter-tasting drugs administered orally, particularly for pediatric patients. The method involves using purinergic receptor inhibitors to modulate the taste of active pharmaceutical ingredients in medications, nutrients, or dietary supplements. This innovation aims to improve patient compliance, especially in underdeveloped countries where medical supervision is lacking, by addressing the challenges of bitter-tasting medications, which can impact treatment adherence and health outcomes, particularly for children with conditions like HIV. [Extracted from the article]

A patent application titled "Interconnected Active Ingredient Containing Pouches" was published online by inventors from Sweden. The invention involves pouches interconnected to deliver active ingredients, such as nicotine, through buccal administration. The interconnected pouches allow users to customize their dosage and prevent dilution or swallowing, enhancing the user experience. The patent application details the design and functionality of the interconnected pouches for efficient delivery of active ingredients. [Extracted from the article]

Recent research from the Federal University Santa Maria in Brazil has focused on developing pediatric-friendly oral suspensions of pyrimethamine for treating congenital toxoplasmosis. The study found that the suspensions were stable, had fast dissolution rates, and met microbial safety requirements. The research concluded that these oral suspensions are easy to prepare and contain safe components, providing an alternative treatment for congenital toxoplasmosis in children. [Extracted from the article]

A patent application titled "Formulations For Oral Administration Of Active Agents" by inventors from Israel has been published online by Entera Bio Ltd. The application focuses on drug delivery systems for oral administration of therapeutically active agents, particularly polypeptides like proteins. The invention involves compositions with SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate) and protective agents like antacid compounds or protease inhibitors to enhance absorption and bioavailability of the active agents. This patent application addresses challenges related to degradation and poor absorption of peptides and proteins in the digestive system, offering potential advancements in pharmaceutical formulations for oral administration. [Extracted from the article]

Researchers from Fukuyama University in Japan conducted a study on the distribution of 5-Aminosalicylic acid (5-ASA) in the intestinal membrane of rats after oral administration. The study found that the distribution of 5-ASA in the proximal intestine was limited by factors such as regional luminal pH, low solubility, and saturable membrane permeability. The research suggests that higher oral doses of 5-ASA may lead to more delivery to the distal intestine due to restricted absorption in the small intestine. This study provides valuable insights into the pharmacokinetics of 5-ASA therapy for conditions like ulcerative colitis. [Extracted from the article]

A recent study conducted at the Second Affiliated Hospital of Mudanjiang Medical University in China explored the impact of early oral administration of doxycycline on macrolide resistance in children with Mycoplasma pneumoniae pneumonia (MPP). The study involved 164 children and found that early oral administration of doxycycline was safe and effective in relieving symptoms in children with macrolide-resistant MPP, reducing the duration of macrolide use, and lowering the incidence of macrolide resistance. The research suggests that this treatment approach could be beneficial for managing MPP in children. [Extracted from the article]

Researchers at the Medical University of Vienna conducted a study on brain ischemia and nimodipine therapy after aneurysmal subarachnoid hemorrhage. The study found that nimodipine levels in the cerebrospinal fluid were significantly higher after intravenous administration compared to oral administration. This suggests that intravenous administration may be more effective in impeding life-threatening cerebral ischemia. The research was supported by the Austrian Science Fund and has been peer-reviewed. [Extracted from the article]

A recent study conducted at Shanghai University of Traditional Chinese Medicine focused on the characterization of active alkaloids and metabolites in rats after oral administration of Zuojin Pill, a traditional Chinese medicine used for gastric disorders. The research utilized advanced bioinformatics and molecular docking analyses to identify 33 compounds, including prototype alkaloids and metabolites, with a propensity for gastric distribution. The study concluded that these compounds could be potential active substances in treating gastritis, shedding light on the pharmacodynamic material basis and gastroprotective mechanism of Zuojin Pill. The research was supported by the National Natural Science Foundation of China and the Science and Technology Development Project of Shanghai University of Traditional Chinese Medicine. [Extracted from the article]

Researchers have submitted a patent application for a therapeutic combination of orally administered paclitaxel, a P-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors. The application aims to address the need for more effective therapies for relapsed/refractory lung cancer patients, as current FDA-approved therapies do not provide a response rate greater than 20%. The combination of oral paclitaxel, Encequidar, and pembrolizumab may enhance immune activation and tumor cell death, offering potential benefits for treating solid tumors. [Extracted from the article]

A study conducted at the University of Colorado focused on the pharmacokinetics of D8-Tetrahydrocannabivarin (THCV) and its metabolites in healthy participants. The research found that after oral administration, the main metabolite detected was 11-nor-9-carboxy-D8-THCV (D8-THCV-COOH), with dose linearity observed in the concentration-time curve. The study highlighted the need for further investigation into the possible conversion to the D9-THCV isomer. This research provides valuable insights into the pharmacokinetics of THCV and its metabolites in humans, contributing to the understanding of cannabinoids and their potential pharmacological properties. [Extracted from the article]

A new clinical trial, NCT06701903, is being conducted to evaluate the efficacy, safety, and tolerability of ITI-1284 as a monotherapy treatment for patients with Generalized Anxiety Disorder (GAD) who have not responded adequately to previous treatments. The trial involves a randomized, double-blind, placebo-controlled study with approximately 570 patients planned to be enrolled. The primary outcome measures include the Hamilton Anxiety Rating Scale (HAM-A) and the Clinical Global Impression Scale-Severity (CGI-S) at week 6. The study is set to be completed by June 30, 2027, and is currently recruiting participants in the United States. [Extracted from the article]

A study conducted at the University of Szeged in Hungary focused on the scalability of a combined wet grinding technique for the oral administration of Meloxicam nanosuspension. The research aimed to determine the impact of scaling up on particle size, morphology, crystallinity, and dissolution of the drug. The study found that the scaling-up of the wet grinding technique is feasible with adjustments to milling parameters and excipient amounts, resulting in improved dissolution of the drug. The research was funded by the National Research, Development And Innovation Office and published in the journal Pharmaceutics. [Extracted from the article]

The article discusses a clinical trial, NCT06686758, investigating the efficacy and safety of Sugar cane polysaccharide LC-Z300-01 on proteinuria in patients with diabetic nephropathy. The trial aims to address the increasing incidence of diabetic nephropathy, which is a leading cause of uremia. The study involves 60 participants with diabetic nephropathy who will be randomly assigned to different treatment groups for 24 weeks, with primary and secondary endpoints focusing on changes in proteinuria levels and renal function. The trial is not yet recruiting participants and is set to be completed by December 31, 2025. [Extracted from the article]

Researchers from Hiroshima University Hospital conducted a study on the effects of oral administration of Porphyromonas gingivalis, a periodontal pathogen, on cognitive function in obese mice. The study found that obese mice exposed to P. gingivalis showed cognitive impairment and increased inflammatory cytokine levels in the brain. Microglial activation was observed in the hippocampus and prefrontal cortex of the mice, and depletion of microglia improved cognitive function. The research suggests that microglia play a role in mediating cognitive dysfunction induced by periodontal infection in obesity. [Extracted from the article]

A study conducted at Yanbian University in China compared the pharmacokinetic behaviors of curcumin in rats following oral and intratracheal administration. The research established an LC-MS/MS method to measure curcumin and its conjugates in rat plasma, revealing distinct pharmacokinetic profiles between the two administration routes. Intratracheal administration resulted in higher curcumin plasma concentrations compared to oral administration, suggesting potential therapeutic benefits. This study provides valuable insights for preclinical pharmacokinetic investigations and highlights the potential advantages of inhalation as a drug delivery route. [Extracted from the article]

A patent application titled "Hair Loss Therapy" by inventor Animesh Sinha has been published online by Nirmana Bio Inc. The application describes a pharmaceutical package containing two oral compositions to treat or prevent hair loss, including minoxidil and a 5-alpha reductase inhibitor like finasteride. The method aims to address hair loss in individuals, with a focus on both men and women experiencing this common issue. The patent application provides detailed information on the compositions and methods for treating hair loss. [Extracted from the article]

A patent has been issued for treatments involving nirogacestat, a gamma-secretase inhibitor, by Springworks Therapeutics Inc. The patent focuses on using nirogacestat to treat conditions such as desmoid tumors, which are rare soft tissue tumors that can cause significant morbidity. The patent outlines methods for administering nirogacestat to patients with desmoid tumors, emphasizing dosage, monitoring for adverse reactions, and avoiding certain drug interactions. [Extracted from the article]

The article discusses a clinical trial, NCT06697899, conducted by Shenzhen TargetRx, Inc., to evaluate the effects of food intake on the pharmacokinetic profiles of TGRX-678 in Chinese healthy subjects. The study aims to assess the drug's safety, tolerability, and pharmacokinetic parameters under different food conditions. The trial is designed as a single-center, single-dose, randomized, open-label study with a primary completion date of January 20, 2025. The study is focused on understanding the impact of food on the drug's absorption and distribution in the body. [Extracted from the article]

Janssen Biotech Inc. has been issued a patent for a pharmaceutical composition for oral administration containing Lazertinib, an aminopyrimidine derivative, which shows promise in treating non-small cell lung cancer. The patent details the specific formulation of the composition to ensure improved manufacturability, stability, and bioavailability. This development represents a significant advancement in the field of oncology and pharmaceuticals. [Extracted from the article]

A patent application titled "Multiparticulate Dosage Forms Comprising Deutetrabenazine" has been published online, detailing controlled release oral dosage forms for the administration of deutetrabenazine. Deutetrabenazine is a VMAT2 inhibitor used in the treatment of chorea associated with Huntington's disease and tardive dyskinesia. The dosage forms aim to provide sustained and controlled release of the drug for improved dosing regimens, potentially allowing for once-daily administration. The inventors seek to address the need for alternative dosage forms that maintain the treatment effects of current medications. [Extracted from the article]

A recent study conducted at the University of Tehran explored the potential neuroprotective effects of oral administration of butylated hydroxytoluene (BHT) in a rat model of Alzheimer's disease induced by streptozotocin. The research suggested that BHT may inhibit neuronal ferroptosis, a process implicated in AD pathogenesis, and attenuate AD-related symptoms. While the findings propose BHT as a promising candidate for an anti-AD drug, further research is needed to investigate its applicability in other neurodegenerative models and ferroptosis-related disorders. The study highlights the importance of exploring novel therapeutic approaches for addressing the challenges posed by Alzheimer's disease. [Extracted from the article]

A study conducted at Hanyang University in Ansan, South Korea, focused on developing a novel apixaban-loaded solid self-emulsifying drug delivery system (S-SEDDS) to enhance oral bioavailability. The research optimized the concentration of Aerosil 200 and investigated the physiochemical properties of the S-SEDDS using various techniques. The study concluded that the S-SEDDS formulation significantly improved drug solubility, dissolution, and bioavailability compared to apixaban powder, suggesting potential benefits for poorly water-soluble drugs. [Extracted from the article]

Researchers at Thammasat University conducted a study to enhance the solubility of curcumin, a bioactive compound from turmeric, using solid self-nanoemulsifying drug delivery systems (S-SNEDDS) for oral administration. The study utilized different lactose types as solid carriers and found that the S-SNEDDS formulations significantly improved curcumin solubility compared to curcumin powder. The research also confirmed the compatibility of the excipients and curcumin, suggesting that the S-SNEDDS formulation could enhance curcumin's bioavailability for oral administration. [Extracted from the article]

The patent issued to Amorphical Ltd. focuses on compositions of amorphous calcium carbonate for inhalation, sublingual, or buccal administration. The patent highlights the importance of calcium in the human body and the unique properties of amorphous calcium carbonate compared to other forms. The invention aims to provide new methods for administering amorphous calcium carbonate to treat various diseases and conditions, including cancer, through inhalation, buccal, sublingual, and gingival routes. [Extracted from the article]

Research from Changchun University of Chinese Medicine explores the potential of peptide drugs for treating type 2 diabetes through oral administration. The study highlights the challenges of oral utilization of peptide drugs due to degradation and absorption issues, proposing nano-formulation carriers as a solution. This research offers new insights into alternative treatment options for type 2 diabetes, emphasizing the importance of improving the oral delivery of peptide drugs. [Extracted from the article]

A clinical trial, NCT06664060, is being conducted to evaluate the efficacy of two nutritional supplements, Osteoimplant Complex(R) and Osteoimplant(R), on postoperative symptoms and bone density following mandibular third molar surgery. The study aims to assess the impact of these supplements on tissue repair and postoperative morbidity in oral surgery. The trial involves randomised, double-blind controlled groups and will include 60 lower third molars from 30 patients, with primary outcome measures focusing on dimensional changes and bone density. The study is not yet recruiting participants and is expected to be completed by December 31, 2025. [Extracted from the article]

A recent report from the University of Bourgogne discusses advances in the oral administration of somatostatin receptor ligands for acromegaly treatment. The development of orally administered SRLs offers a promising alternative to injectable SRLs, with key clinical findings showing efficacy in maintaining biochemical control in patients. While long-term maintenance was confirmed for oral octreotide capsules, further research is needed to compare different oral SRLs and study patients who have not received prior injectable SRL treatment. [Extracted from the article]

A patent application by Christoph Gibson discusses a pharmaceutical composition for oral administration of bradykinin B2 receptor antagonists. Bradykinin is a peptide hormone involved in inflammatory processes, and compounds of Formula 1 are proposed as novel antagonists. The invention aims to address challenges in solubility and bioavailability to provide effective treatment for conditions like asthma and Alzheimer's disease. The liquid pharmaceutical composition includes propylene glycol monocaprylate and polyoxyl castor oil, and can be used in capsules for therapy. [Extracted from the article]

A recent study published in Pain & Central Nervous System Week explores the use of berberine and berberine nanoparticles in mitigating scopolamine-induced amnesia in rats. The research involved administering different treatments to male Wistar rats and analyzing their biochemical responses. The results indicated significant differences in plasma and brain parameters among the experimental groups, with berberine nanoparticles showing promise in increasing brain protein levels and improving brain uric acid levels. For more information, the full article can be accessed for free at https://doi.org/10.1093/ajcp/aqae129.048. [Extracted from the article]

The article discusses a clinical trial, NCT06655220, investigating the impact of BI 1815368 on the exposure of metformin in plasma when administered together in healthy subjects. The trial aims to compare the effects of metformin administered alone versus in combination with BI 1815368. The study involves healthy male subjects aged 18 to 50 and is in the recruitment phase, with a completion date set for December 13, 2024. The trial is interventional, with a randomized allocation and crossover design, focusing on the pharmacokinetics of the drugs. [Extracted from the article]

A study conducted at the University of South Florida explored the effects of a novel synthetic ketogenic compound, glycerol tri-acetoacetate (Gly-3AcAc), on elevating blood b-hydroxybutyrate levels in mice under both fasting and fed conditions. The compound was found to induce hyperketonemia within the therapeutic range and showed potential for inducing therapeutic nutritional ketosis without detrimental side effects. Researchers aim to further investigate the compound's efficacy in augmenting metabolic therapy. The study was supported by the University of South Florida and published in the journal Nutrients. [Extracted from the article]

Fertin Pharma A/S in Denmark has been granted a patent for a solid dosage form of a nicotine concentration. The invention aims to provide an oral nicotine formulation that alleviates nicotine cravings effectively while minimizing burning in the throat. The patent details the composition and characteristics of an orally disintegrating nicotine tablet designed to deliver high nicotine concentration and pH levels in the oral cavity within the first 120 seconds of administration. This innovation offers a potential solution for individuals seeking alternatives to traditional nicotine delivery methods. [Extracted from the article]

The article discusses an open-label Phase 1 study conducted by Escient Pharmaceuticals, Inc., focusing on the absorption, metabolism, and excretion of [14C]-EP262 in healthy male participants. The study aims to evaluate the mass balance, pharmacokinetics, and metabolite profiles of a single oral dose of [14C]-EP262. The trial, with the identifier NCT06645704, is currently recruiting participants and is set to be completed by January 2025. The study involves 10 male participants aged 18 to 55 years, meeting specific eligibility criteria, and aims to assess the safety, tolerability, and pharmacological properties of EP262. [Extracted from the article]